Clinical trials of a cryoglobulin filter

Area of Science:

• Nephrology
• Hematology
• Medical Devices

Background:

• Cryoglobulinemia is a condition involving abnormal proteins that can lead to organ damage.
• Patients unresponsive to prednisone or immunosuppressive drugs often require plasmapheresis.
• Existing treatments may not be sufficient for all cryoglobulinemia patients.

Purpose of the Study:

• To evaluate the safety and efficacy of a high-capacity cryoglobulin filter (Cryofilter).
• To assess the filter's performance in patients with cryoglobulinemia refractory to standard therapies.
• To adhere to FDA investigational Device Exemption guidelines.

Main Methods:

• A cryofilter with a 0.135 m2 membrane and 4.3-micron pores was used.
• Plasma was filtered at 4°C to selectively remove cryoglobulins.
• Safety assessed via vital signs, complement activation, and clinical scores over 10 treatments.
• Efficacy evaluated by comparing cryoglobulin sieving to albumin, immunoglobulins, and fibrinogen.

Main Results:

• All seven patients completed 10 treatments without significant complement activation or discomfort.
• The cryofilter demonstrated high selectivity for cryoglobulins, especially at high concentrations.
• No adverse events related to the filtration procedure were reported.
• Significant improvement in clinical symptoms was observed across all patients.

Conclusions:

• The cryofilter is a safe and effective device for treating cryoglobulinemia.
• Cryofiltration offers a promising therapeutic option for patients unresponsive to conventional treatments.
• The device shows potential for selective removal of cryoglobulins during plasmapheresis.